Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-1962 vs Standard of Care in Aneurysmal Subarachnoid Hemorrhage
NCT02893826Phase 1Terminated
- Sponsor
- Edge Therapeutics
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of EG-1962 in aneurysmal subarachnoid hemorrhage (SAH), sponsored by Edge Therapeutics. Primary endpoints: Incidence and severity of adverse events at 90 Days and Proportion of subjects with delayed cerebral infarctions present on CT at 30 Days. Started Sep 2016; status: terminated.
02
Drugs
EG-1962
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT02893826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893826.